Dapaconazole is an antifungal drug candidate. Phase II trials showed that Dapaconazole tosylate is non-inferior to ketoconazole when used at a dose of 20 mg/day for 28 consecutive days for the treatment of PV. Dapaconazole also demonstrated a good safety profile. References: Gobbato AA, Babadópulos T, Gobbato CA, Ilha Jde O, Gagliano-Jucá T, De Nucci G. A randomized double-blind, non-inferiority Phase II trial, comparing dapaconazole tosylate 2% cream with ketoconazole 2% cream in the treatment of Pityriasis versicolor. Expert Opin Investig Drugs. 2015 Nov;24(11):1399-407. doi: 10.1517/13543784.2015.1083009. Epub 2015 Sep 30. PubMed PMID: 26419668.

纯度：≥98%

CAS：1269726-67-1